Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 2
1985 5
1986 6
1987 7
1988 7
1989 4
1990 5
1991 7
1992 1
1993 6
1994 7
1995 3
1996 6
1997 11
1998 4
1999 7
2000 3
2001 9
2002 8
2003 8
2004 14
2005 16
2006 7
2007 13
2008 12
2009 15
2010 13
2011 19
2012 14
2013 23
2014 23
2015 18
2016 13
2017 25
2018 35
2019 22
2020 34
2021 50
2022 34
2023 14
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

478 results

Results by year

Filters applied: . Clear all
Page 1
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
Zhou C, Solomon B, Loong HH, Park K, Pérol M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, Mak MP, Santini FC, Elamin YY, Drilon A, Wolf J, Payakachat N, Uh MK, Rajakumar D, Han H, Puri T, Soldatenkova V, Lin AB, Lin BK, Goto K; LIBRETTO-431 Trial Investigators. Zhou C, et al. Among authors: ardizzoni a. N Engl J Med. 2023 Nov 16;389(20):1839-1850. doi: 10.1056/NEJMoa2309457. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870973 Clinical Trial.
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Dingemans AC, Früh M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks LE, Lantuejoul S, Peters S, Reguart N, Rudin CM, De Ruysscher D, Van Schil PE, Vansteenkiste J, Reck M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Dingemans AC, et al. Among authors: ardizzoni a. Ann Oncol. 2021 Jul;32(7):839-853. doi: 10.1016/j.annonc.2021.03.207. Epub 2021 Apr 20. Ann Oncol. 2021. PMID: 33864941 Free PMC article. No abstract available.
Regolazione del prezzo e rimborso dei farmaci: comparatori, endpoint e ruolo della costo-efficacia.
Jommi C, Apolone G, Scroccaro G, Acciai V, Addis A, Ardizzoni A, Bernardini R, Bortolami A, Brigido A, Buzzetti G, Canonico PL, Caprari F, Centanni S, Cernetti C, Cicchetti A, Corsico G, Damele F, de Braud F, Manurita S, Mennini FS, Olivi I, Parretta F, Pippo L, Pulimeno S, Riccaboni M, Rossi G, Saleri C, Sinibaldi A, Spandonaro F, Stefenoni C, Visentin E, Viale P, Zapparelli G, Popoli P. Jommi C, et al. Among authors: ardizzoni a. Glob Reg Health Technol Assess. 2022 Sep 28;9:99-104. doi: 10.33393/grhta.2022.2475. eCollection 2022 Jan-Dec. Glob Reg Health Technol Assess. 2022. PMID: 36628317 Free PMC article. Italian.
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial.
Sartore-Bianchi A, Lonardi S, Martino C, Fenocchio E, Tosi F, Ghezzi S, Leone F, Bergamo F, Zagonel V, Ciardiello F, Ardizzoni A, Amatu A, Bencardino K, Valtorta E, Grassi E, Torri V, Bonoldi E, Sapino A, Vanzulli A, Regge D, Cappello G, Bardelli A, Trusolino L, Marsoni S, Siena S. Sartore-Bianchi A, et al. Among authors: ardizzoni a. ESMO Open. 2020 Sep;5(5):e000911. doi: 10.1136/esmoopen-2020-000911. ESMO Open. 2020. PMID: 32988996 Free PMC article. Clinical Trial.
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer.
Noronha A, Belugali Nataraj N, Lee JS, Zhitomirsky B, Oren Y, Oster S, Lindzen M, Mukherjee S, Will R, Ghosh S, Simoni-Nieves A, Verma A, Chatterjee R, Borgoni S, Robinson W, Sinha S, Brandis A, Kerr DL, Wu W, Sekar A, Giri S, Chung Y, Drago-Garcia D, Danysh BP, Lauriola M, Fiorentino M, Ardizzoni A, Oren M, Blakely CM, Ezike J, Wiemann S, Parida L, Bivona TG, Aqeilan RI, Brugge JS, Regev A, Getz G, Ruppin E, Yarden Y. Noronha A, et al. Among authors: ardizzoni a. Cancer Discov. 2022 Nov 2;12(11):2666-2683. doi: 10.1158/2159-8290.CD-22-0111. Cancer Discov. 2022. PMID: 35895872 Free PMC article.
Real-world data: come possono aiutare a migliorare la qualità dell’assistenza.
Corrao G, Alquati G, Apolone G, Ardizzoni A, Buzzetti G, Canonica GW, Conte P, Crovato E, Damele F, La Vecchia C, Maggioni AP, Mantovani A, Marangi M, Marrocco W, Messori A, Padovani A, Rambaldi A, Ricciardi W, di Meana FR, Spandonaro F, Tozzi V, Mancia G. Corrao G, et al. Among authors: ardizzoni a. Glob Reg Health Technol Assess. 2021 Sep 20;8:134-139. doi: 10.33393/grhta.2021.2286. eCollection 2021 Jan-Dec. Glob Reg Health Technol Assess. 2021. PMID: 36627865 Free PMC article. Italian.
Novel therapeutic strategies for recurrent SCLC.
Moliner L, Zhang B, Lamberti G, Ardizzoni A, Byers LA, Califano R. Moliner L, et al. Among authors: ardizzoni a. Crit Rev Oncol Hematol. 2023 Jun;186:104017. doi: 10.1016/j.critrevonc.2023.104017. Epub 2023 May 5. Crit Rev Oncol Hematol. 2023. PMID: 37150311 Review.
Emerging therapies in malignant pleural mesothelioma.
Cinausero M, Rihawi K, Cortiula F, Follador A, Fasola G, Ardizzoni A. Cinausero M, et al. Among authors: ardizzoni a. Crit Rev Oncol Hematol. 2019 Dec;144:102815. doi: 10.1016/j.critrevonc.2019.102815. Epub 2019 Oct 5. Crit Rev Oncol Hematol. 2019. PMID: 31670225 Review.
478 results